This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jacobs, T. W. Articles by Schnitt, S. J. Search for Related Content PubMed PubMed Citation Articles by Jacobs, T. W. Articles by Schnitt, S. J.

Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer

From the Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; and PhenoPath Laboratories and IRIS, Seattle, WA.

Address reprint requests to Stuart J. Schnitt, MD, Department of Pathology, Beth Israel Deaconess Medical Center–East Campus, 330 Brookline Ave, Boston, MA 02215; email sschnitt{at}caregroup harvard.edu.

ABSTRACT

PURPOSE: To compare fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in the determination of HER-2/neu status of breast cancers.

MATERIALS AND METHODS: FISH and IHC for HER-2/neu were performed on formalin-fixed paraffin sections of 100 consecutive invasive breast cancers. FISH was performed at Beth Israel Deaconess Medical Center, Boston, MA, using the Oncor/Ventana INFORM kit (Ventana Medical Systems, Tucson, AZ; formerly sold by Oncor, Inc, Gaithersburg, MD) in a laboratory certified as proficient in this procedure. IHC was performed at PhenoPath Laboratories, Seattle, WA, using a polyclonal antibody to the HER-2/neu protein. FISH and IHC were analyzed in a blinded fashion, and the results were then compared. Procedure and interpretation times and reagent costs for FISH and IHC were also compared.

RESULTS: HER-2/neu was amplified by FISH in 26% of cases, and 23% were HER-2/neu–positive by IHC. FISHand IHC were both assessable in 90 cases. Concordance between FISH and IHC results was seen in 82 of these cases (91%, P < .001). The FISH procedure required more technologist time and more interpretation time per case for the pathologist than IHC. Reagent costs were substantially higher for FISH than for IHC.

CONCLUSION: There is a high level of correlation between FISH and IHC in the evaluation of HER-2/neu status of breast cancers using formalin-fixed paraffin-embedded specimens. Although the choice of which assay to use should be left for individual laboratories to make based on technical and economic considerations, our results may make it difficult to justify the routine use of FISH for determination of HER-2/neu status in breast cancer.

This article has been cited by other articles:

				C L Hyun, H E Lee, K S Kim, S-W Kim, J H Kim, G Choe, and S Y Park The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer J. Clin. Pathol., March 1, 2008; 61(3): 317 - 321. [Abstract] [Full Text] [PDF]

				C. A. Hudis Trastuzumab -- Mechanism of Action and Use in Clinical Practice N. Engl. J. Med., July 5, 2007; 357(1): 39 - 51. [Full Text] [PDF]

				A. M. Gonzalez-Angulo, G. N. Hortobagyi, and F. J. Esteva Adjuvant Therapy with Trastuzumab for HER-2/neu-Positive Breast Cancer Oncologist, September 1, 2006; 11(8): 857 - 867. [Abstract] [Full Text] [PDF]

				M. F. Press, G. Sauter, L. Bernstein, I. E. Villalobos, M. Mirlacher, J.-Y. Zhou, R. Wardeh, Y.-T. Li, R. Guzman, Y. Ma, et al. Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials Clin. Cancer Res., September 15, 2005; 11(18): 6598 - 6607. [Abstract] [Full Text] [PDF]

				L. G. Dressler, D. A. Berry, G. Broadwater, D. Cowan, K. Cox, S. Griffin, A. Miller, J. Tse, D. Novotny, D. L. Persons, et al. Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients J. Clin. Oncol., July 1, 2005; 23(19): 4287 - 4297. [Abstract] [Full Text] [PDF]

				F. Millanta, M. Calandrella, S. Citi, D. Della Santa, and A. Poli Overexpression of HER-2 in Feline Invasive Mammary Carcinomas: An Immunohistochemical Survey and Evaluation of Its Prognostic Potential Vet. Pathol., January 1, 2005; 42(1): 30 - 34. [Abstract] [Full Text] [PDF]

				B. M. Slomovitz, R. R. Broaddus, T. W. Burke, N. Sneige, P. T. Soliman, W. Wu, C. C. Sun, M. F. Munsell, D. M. Gershenson, and K. H. Lu Her-2/neu Overexpression and Amplification in Uterine Papillary Serous Carcinoma J. Clin. Oncol., August 1, 2004; 22(15): 3126 - 3132. [Abstract] [Full Text] [PDF]

				H. Yaziji, L. C. Goldstein, T. S. Barry, R. Werling, H. Hwang, G. K. Ellis, J. R. Gralow, R. B. Livingston, and A. M. Gown HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods JAMA, April 28, 2004; 291(16): 1972 - 1977. [Abstract] [Full Text] [PDF]

				E. B. Elkin, M. C. Weinstein, E. P. Winer, K. M. Kuntz, S. J. Schnitt, and J. C. Weeks HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis J. Clin. Oncol., March 1, 2004; 22(5): 854 - 863. [Abstract] [Full Text] [PDF]

				L. M. Gjerdrum, B. S. Sorensen, E. Kjeldsen, F. B. Sorensen, E. Nexo, and S. Hamilton-Dutoit Real-Time Quantitative PCR of Microdissected Paraffin-Embedded Breast Carcinoma: An Alternative Method for HER-2/neu Analysis J. Mol. Diagn., February 1, 2004; 6(1): 42 - 51. [Abstract] [Full Text]

				P. Heinmoller, C. Gross, K. Beyser, C. Schmidtgen, G. Maass, M. Pedrocchi, and J. Ruschoff HER2 Status in Non-Small Cell Lung Cancer: Results from Patient Screening for Enrollment to a Phase II Study of Herceptin Clin. Cancer Res., November 1, 2003; 9(14): 5238 - 5243. [Abstract] [Full Text] [PDF]

				P. Lal, P. A. Salazar, M. Ladanyi, and B. Chen Impact of Polysomy 17 on HER-2/neu Immunohistochemistry in Breast Carcinomas without HER-2/neu Gene Amplification J. Mol. Diagn., August 1, 2003; 5(3): 155 - 159. [Abstract] [Full Text] [PDF]

				M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J.-Y. Zhou, and L. Bernstein Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens J. Clin. Oncol., July 15, 2002; 20(14): 3095 - 3105. [Abstract] [Full Text] [PDF]

				C. Van Poznak, L. Tan, K. S. Panageas, C. D. Arroyo, C. Hudis, L. Norton, and A. D. Seidman Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer J. Clin. Oncol., May 1, 2002; 20(9): 2319 - 2326. [Abstract] [Full Text] [PDF]

				F. J. Esteva, V. Valero, D. Booser, L. T. Guerra, J. L. Murray, L. Pusztai, M. Cristofanilli, B. Arun, B. Esmaeli, H. A. Fritsche, et al. Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast Cancer J. Clin. Oncol., April 1, 2002; 20(7): 1800 - 1808. [Abstract] [Full Text] [PDF]

				A. J. Khan, B. L. King, B. D. Smith, G. L. Smith, M. P. DiGiovanna, D. Carter, and B. G. Haffty Characterization of the HER-2/neu Oncogene by Immunohistochemical and Fluorescence in Situ Hybridization Analysis in Oral and Oropharyngeal Squamous Cell Carcinoma Clin. Cancer Res., February 1, 2002; 8(2): 540 - 548. [Abstract] [Full Text] [PDF]

				D. W. Nichols, D. J. Wolff, S. Self, J. S. Metcalf, D. Jacobs, R. Kneuper-Hall, and J. C. Cate IV A Testing Algorithm for Determination of HER2 Status in Patients with Breast Cancer Ann. Clin. Lab. Sci., January 1, 2002; 32(1): 3 - 11. [Abstract] [Full Text] [PDF]

				W. K. Funkhouser and K. Kaiser-Rogers Significance of, and Optimal Screening for, HER-2 Gene Amplification and Protein Overexpression in Breast Carcinoma Ann. Clin. Lab. Sci., October 1, 2001; 31(4): 349 - 358. [Abstract] [Full Text] [PDF]

				A. Thor Are Patterns of HER-2/neu Amplification and Expression Among Primary Tumors and Regional Metastases Indicative of Those in Distant Metastases and Predictive of Herceptin Response? J Natl Cancer Inst, August 1, 2001; 93(15): 1120 - 1121. [Full Text] [PDF]

				R. Simon, A. Nocito, T. Hubscher, C. Bucher, J. Torhorst, P. Schraml, L. Bubendorf, M. M. Mihatsch, H. Moch, K. Wilber, et al. Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer J Natl Cancer Inst, August 1, 2001; 93(15): 1141 - 1146. [Abstract] [Full Text] [PDF]

				A. D. Seidman, M. N. Fornier, F. J. Esteva, L. Tan, S. Kaptain, A. Bach, K. S. Panageas, C. Arroyo, V. Valero, V. Currie, et al. Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification J. Clin. Oncol., May 15, 2001; 19(10): 2587 - 2595. [Abstract] [Full Text] [PDF]

				H. Yamauchi, V. Stearns, and D. F. Hayes When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2334 - 2356. [Abstract] [Full Text] [PDF]

				A. Lebeau, D. Deimling, C. Kaltz, A. Sendelhofert, A. Iff, B. Luthardt, M. Untch, and U. Lohrs HER-2/neu Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ Hybridization J. Clin. Oncol., January 15, 2001; 19(2): 354 - 363. [Abstract] [Full Text] [PDF]

				G. Pauletti, S. Dandekar, H. Rong, L. Ramos, H. Peng, R. Seshadri, and D. J. Slamon Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry J. Clin. Oncol., November 1, 2000; 18(21): 3651 - 3664. [Abstract] [Full Text] [PDF]

				M. Tanner, D. Gancberg, A. Di Leo, D. Larsimont, G. Rouas, M. J. Piccart, and J. Isola Chromogenic in Situ Hybridization : A Practical Alternative for Fluorescence in Situ Hybridization to Detect HER-2/neu Oncogene Amplification in Archival Breast Cancer Samples Am. J. Pathol., November 1, 2000; 157(5): 1467 - 1472. [Abstract] [Full Text] [PDF]

				Y. Nieto, P. J. Cagnoni, S. Nawaz, E. J. Shpall, R. Yerushalmi, B. Cook, P. Russell, J. McDermit, J. Murphy, S. I. Bearman, et al. Evaluation of the Predictive Value of Her-2/neu Overexpression and p53 Mutations in High-Risk Primary Breast Cancer Patients Treated With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation J. Clin. Oncol., May 10, 2000; 18(10): 2070 - 2080. [Abstract] [Full Text] [PDF]

				S Wang, M H Saboorian, E Frenkel, L Hynan, S T Gokaslan, and R Ashfaq Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays J. Clin. Pathol., May 1, 2000; 53(5): 374 - 381. [Abstract] [Full Text] [PDF]

				S. Seelig, T. W. Jacobs, S. J. Schnitt, A. M. Gown, and H. Yaziji Fluorescence In Situ Hybridization Versus Immunohistochemistry: Importance of Clinical Outcome J. Clin. Oncol., November 1, 1999; 17(11): 3690 - 3692. [Full Text] [PDF]

				T. W. Jacobs, A. M. Gown, H. Yaziji, M. J. Barnes, and S. J. Schnitt Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration-Approved Scoring System J. Clin. Oncol., July 1, 1999; 17(7): 1983 - 1983. [Abstract] [Full Text] [PDF]